Pharma companies fined $4.5m over product claims


They admitted to making false or misleading representations in the marketing of two pain relief products GlaxoSmithKline Consumer Healthcare Australia and Novartis Consumer Health Australasia have been ordered to pay $4.5 million in penalties over false or misleading representations in the marketing of their Voltaren Osteo Gel and Voltaren Emulgel pain relief products. From January

This content is restricted. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous ‘Tawdry turfism’ from doctor group
Next Support for e-scripts